5 February 2015

2RT™ Makes Headline in Peer-Review Publication

Adelaide, Australia, 05 February 2015 – Ellex Medical Lasers Limited (ASX:ELX), a pioneer in medical technologies for the diagnosis and treatment of eye disease, today announced that its proprietary 2RT™ (Retinal Rejuvenation Therapy) has been featured on the cover of the February 2015 edition of the Journal of the Federation of American Societies for Experimental Biology (FASEB Journal).

Described as “Nanosecond Laser Burst Reverses Macular Degeneration”, the cover article summarises the 24-month data of 50 patients treated with a single pulse of 2RT™ for early Age-Related Macular Degeneration (AMD). The article concludes that 2RT™ reduces drusen load at two years and thereby offers the potential to reduce the progression of AMD.

According to Ellex CEO Tom Spurling, the selection of 2RT™ as the cover story of the FASEB Journal is a significant milestone for the 2RT™ project.

“We are pleased that this prestigious peer-review journal has published the 24-month data for 2RT. The fact that 2RT was chosen as the cover story highlights the significance of this data. It also shows that 2RT is breaking new ground in the management of AMD patients. This is an exciting time for Ellex,” commented Mr. Spurling.

“We are confident that the FASEB publication will bring greater awareness to the 2RT project and support continued sales of 2RT units, which commenced to early adopters in mid-2014 in Europe, Australia, New Zealand and key Asian countries,” continued Mr. Spurling.

The abstract of the 2RT FASEB Journal article, “Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage”, is available at http://www.fasebj.org/content/29/2/696.abstract.

ABOUT 2RT
Retinal Rejuvenation Therapy (2RT™) delivers nanosecond pulses of laser energy to stimulate a natural, biological healing response in the eye to stimulate a process of cellular rejuvenation to preserve and/or improve functional vision, reducing disease progression. These nanosecond pulses generate a response by retinal pigment epithelium (RPE) melanosomes, without causing heat to escape beyond the RPE cell walls. These pulses cause damage to the internal cell structure only: they do not break the cell’s outer membrane. This process of regeneration acts to rejuvenate the entire transport mechanism of the retina, improving visual function and reducing disease progression. This breakthrough approach retains the therapeutic effect of laser therapy whilst eliminating the thermal tissue damage inherent in conventional retinal photocoagulation laser treatment.

2RT™ has a CE Mark (Conformité Européenne) and is included on the Australian Register of Therapeutic Goods (ARTG) for the treatment of early AMD.
For additional information about 2RT, please visit www.ellex.com/2RT.

ABOUT ELLEX
Ellex Medical Lasers Limited (ASX:ELX) is a pioneer in the development of medical technologies for the diagnosis and treatment of eye disease. With more than 20,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, France, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products. On 31 December 2013 Ellex acquired the Canaloplasty microcatheter-based glaucoma surgical treatment from iScience Interventional, Inc.

For additional information about Ellex and its products, please visit www.ellex.com.

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5293 | M +61 417 818 658
tspurling@ellex.com

Maria Maieli, Company Secretary
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200
mmaieli@ellex.com

Victor Previn, Chairman
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5200 | M +61 414 661 994
vprevin@ellex.com

For media enquires please contact:

Kate Hunt, Corporate Communications
Ellex Medical Lasers Limited
82 Gilbert Street, Adelaide, SA, 5000
W +61 8 8104 5214
khunt@ellex.com